cyrilzakka/clinical-trials huggingface dataset:
Individuals With Lumbar Disc Hernia Exercising With Virtual Reality Glasses

The purpose of this research; exercise performed with virtual reality glasses for individuals with lumbar disc herniation; The aim of this study is to examine the effects on pain, activities of daily living, quality of life and falling.

The purpose of this research; exercise performed with virtual reality glasses for individuals with lumbar disc herniation; The aim of this study is to examine the effects on pain, activities of daily living, quality of life and falling.

This research was carried out experimentally with pretest-posttest control group.

The research was carried out between December 2019 and August 2022. The research was carried out in the Physical Therapy Unit of Erzurum Atatürk University Health Practice and Research Center.

The universe of the research; It consisted of 68 patients with LDH who came to Atatürk University Health Application and Research Center Physical Therapy and Rehabilitation Unit between 13 September 2022 and 7 January 2022.

n data collection, "Patient Identification Form" (Appendix-5), "Visual Analog Scale" (Appendix-6), "Oswestry Disability Index" (Appendix-7), "SF-36 Quality of Life Scale" (Appendix-8) and Falling Risk Score result is used.The patients in the experimental and control groups were first given training on protection of back health and exercise.

The patients in the experimental group did waist exercises with virtual reality glasses for 2 sessions, 28 sessions in total, every weekday.

Eligibility Criteria:
Inclusion Criteria:

* Being literate.
* Not having a physical disability that prevents them from doing the exercises.
* Not have an uncontrolled chronic or acute illness.
* Not having a vision problem that cannot be controlled by assistive methods.
* Not having a vertigo problem
* To be cognitively competent.
* Not having any musculoskeletal surgery in the last 6 months
* Not having knee joint disease
* To be able to complete the measurement with the balance device
* Having a body mass index below 40

Exclusion Criteria:

* To have a medium and high fall risk score in the measurement made with the balance device
* Experiencing chronic pain.
Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma

This is a prospective single arm phase II study, and the purpose of this study is to evaluate the efficiency of R2 regimen (rituximab \& lenalidomide) combined with intravitreal methotrexate and followed by lenalidomide maintenance in newly-diagnosed primary intraocular lymphoma. Progression free survival (PFS) of the cohort is the primary endpoint.

All the patients will be treated with R2 regimen （Rituximab 375mg/m2 IV d1, lenalidomide 25mg d1-21, 28 days per cycle) as induction regimen, meanwhile intravitreal methotrexate was given at a dose of 400ug for 16 doses.

The response will be evaluated every 3 cycles. After 3 Cycles, patients who achieved complete remission (CR) or partial remission (PR) will receive 3 more cycles of R2 regimen. The patients with stable disease (SD) or progressed disease (PD) will withdraw from the trial and receive salvage regimens. After total 6 induction cycles, the investigators evaluate the efficiency again, the patients with CR or PR will go to lenalidomide maintenance for 2 years or until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion. And the patients with SD or PD will receive salvage regimen.

During following-up, surveillance ophthalmologic examination and brain magnetic resonance imaging (MRI) scans can be performed every 3 months up to the first 2 years, followed by doctor visit every 6 months up to 5 years or the disease relapses.

Eligibility Criteria:
Inclusion Criteria:

* Newly-diagnosed primary vitreoretinal lymphoma
* ECOG≤2
* creatinine clearance rate (CCR) ≥ 60ml/h, according to Cockcroft-Gault
* Total bilirubin \< 2 upper limits of normal, alanine aminotransferase（ALT） \< 3 upper limits of normal
* Sign the Informed consent
* Women of childbearing potential must understand that the study medication could have a potential teratogenic risk. They should undergo complete contraception during the study period.
* Male subjects must agree to use condoms throughout study drug therapy.

Exclusion Criteria:

* primary central nervous system lymphoma involved eyes and brain
* systemic B cell lymphoma involved eyes
* Pre-existing uncontrolled active infection
* Clinical evidence of grade 3 or 4 heart failure as defined by the New York Heart Association criteria
* Pregnancy or active lactation
* Co-existing tumors
* HIV（human immunodeficiency virus） or HBV（hepatitis B virus） or HCV（hepatitis C virus） infection
Assessment of the Uterus Using Ultrasonographic Elastography in Women with Dysmenorrhea

The aim of this study is to perform sonoelastographic assessment of the uterus in patients diagnosed with primary dysmenorrhea and to compare these measurements with sonoelastographic evaluations of the uteri in asymptomatic individuals. This will enable, for the first time, the demonstration of whether the elasticity of the myometrial tissue contributes to the etiology of primary dysmenorrhea.

Secondary Objectives: To determine whether there is a correlation between the severity of primary dysmenorrhea and ultrasonographic markers.


Eligibility Criteria:
Inclusion Criteria:

1. Women aged 18-40 years.
2. Women with primary dysmenorrhea who are willing to participate in the study.
3. Women without primary or secondary dysmenorrhea who agree to participate as a control group.

Exclusion Criteria:

1. Women with secondary dysmenorrhea.
2. Patients with underlying uterine or adnexal pathologies (e.g., endometrial polyps, adenomyosis, uterine fibroids, adnexal masses, ovarian pathologies and cysts) identified via ultrasonography.
3. Individuals with a history of uterine surgery.
4. Individuals with a history of pelvic surgery.
5. Individuals who have delivered via normal spontaneous vaginal delivery or cesarean section.
Auricular Acupressure as a Non-Opioid Adjuvant in Opioid Tolerant Patients

The purpose of this study is to determine if the addition of auricular acupressure to the typical pharmacological regimen given to patients on the chronic pain/addiction service will lower pain scores and decrease pain medication usage.

Participants will be asked to complete baseline questionnaires. After completion, a study interventionist will place 10 adhesive acupressure pads./seeds on the participant's ears, 5 acupressure pads per ear. The pads will be placed on specific sites of the ear that are thought to help with pain and overall well-being. Over the course of 3 days, participants will be asked to apply a small amount of pressure with their finger to each of the pads and answer study questionnaires.

This feasibility trial is being performed in collaboration with the Battlefield Auricular Acupressure (BAApress) Training and Intervention Fidelity study (IRB00084011).

Eligibility Criteria:
Inclusion Criteria:

* Age \> or equal to 18
* History of documented chronic pain with or without opioid use disorder (Polysubstance abuse or opioid use disorder or opioid narcotic use documented as home medication)
* Estimated length of stay (admission) at least 5 days at the time of recruitment
* Able to read and understand informed consent form

Exclusion Criteria:

* Patient refusal
* Patients with a known history of leaving against medical advice (AMA)
* only English-speaking participants will be eligible.
* Inability to communicate via telephone
* Participants with a history of skin disease (e.g., psoriasis) involving the ear, adhesive allergy, recent scar tissue on ear, or current abrasions or cuts on ear,
* Cognitive impairment (delirium, dementia)
* Physical impairment preventing them from applying pressure to the beads
* Patients with cardiac pacemakers (contraindication to POINTER PAL)
* Use of some types of hearing aids (obstructing the placement of beads)
* Any chronic or acute illness or psychiatric conditions that would impact adherence to the study requirements
the PHENOSAR Trial: Use of Antibiotics in Treatment of Sarcoidosis

In this study it is investigated whether treatment with azithromycin in combination with doxycycline reduces the bacterial load of C. acnes in granulomatous tissue of patients with sarcoidosis and subsequently decreases the inflammatory activation measured by FDG uptake and serum biomarkers.

Sarcoidosis is a multisystemic disease with unknown origin mostly affecting intrathoracic lymph nodes, lungs and skin. Sarcoidosis is characterized by the formation of non-caseating granulomas causing a variety of symptoms based on the organs involved. Although frequently described as a benign disease, mortality rate has been estimated to be around 11.0 per 1000 person-years in patients with sarcoidosis, with respiratory failure as the most common cause of death in the western world.

The main treatment indication in sarcoidosis is risk of organ failure. In the literature the need for systemic treatment varies between 20-70%. Since there is no curative treatment for sarcoidosis, treatment is focused on suppression of the inflammation. This is usually done with the use of immunosuppressive drugs, such as prednisone and/or methotrexate, and in patients with severe refractory disease infliximab. It is well known that treatment with immunosuppressive drugs is associated with burdensome side effects for patients and impaired quality of life.

Considerable research has been done on the possible role C. acnes in the pathogenesis of sarcoidosis. In a recent work of our own group it was shown that presence of C. acnes within granulomatous tissue can be detected in 41% of Dutch patients with sarcoidosis. Azithromycin has an inhibiting effect on several bacterial infections, such as C. acnes. Therefore, sarcoidosis patients with C. acnes in the granulomatous tissue might benefit from treatment with azithromycin. Given the fact that microbial resistance to azithromycin is relatively easy to develop, it is common practice to treat C. acnes with a combination of azithromycin and doxycycline.

Eligibility Criteria:
Inclusion Criteria:

* Biopsy proven sarcoidosis.
* No treatment indication for the sarcoidosis
* Inflammatory activity according to FDG-PET scan at baseline
* SUVmax above 3 in the lung and/or above 5 in mediastinum/hili

Exclusion Criteria:

* Increased duration of QT interval (\>440ms for men and \>450ms for women) on ECG
* Hearing deficits, as this is a possible side effect of azithromycin
* Being pregnant or breastfeeding at time of inclusion
Quadratus Lumborum Block by Paraspinous Sagittal Shift Approach for Hip Surgery

The quadratus lumborum block (QLB) was first described by Blanco. it is a compartment block procedure during which a local anesthetic is injected into the muscle plane of the quadratus lumborum (QL) muscle under ultrasound guidance Currently, QLB is divided into four types based on the injection point of the local anesthetic: lateral, anterior, posterior, and intramuscular QLB. QLB is widely used for various types of abdominal surgeries (

the investigators will evaluate the anesthetic efficacy of quadratus lumborum block by paraspinous sagittal shift approach for hip surgery by injecting 30 ml of 0. 5% bupivacaine.

Eligibility Criteria:
Inclusion Criteria:

-ASA I and II

Exclusion Criteria:

* Contraindications for regional blocks (eg. Patient refusal Infection at the injection site, coagulopathy)
* Allergic reaction to drugs.
* opium addiction, any drug or substance abuse and chronic treatment with opium, non-steroidal anti-inflammatory drugs
Radical Mastoidectomy Versus Mastoid Oblitration in Pediatric Population

Chronic otitis media (COM) has a significant impact on health issues since prehistoric time. It is a global disease, seen in all the continents of world having different environmental and socioeconomic background. COM is characterized as a permanent abnormality of the pars tensa or flaccida, most likely a result of earlier acute otitis media, negative middle ear pressure or otitis media with effusion. COM squamous active (cholesteatoma) is a type of COM, which is a mass formed by keratinizing squamous epithelium in the middle ear and/or mastoid, subepithelial connective tissue and by the progressive accumulation of keratin debris with/without surrounding inflammatory reaction.

Paediatric cholesteatoma spread more extensively through the temporal bone than in adult as the temporal bone in children is well pneumatized. The disease in children is frequently more extensive and expanding, with more involvement of the peri-labyrinthine cells and petrous apex. It is a commonly encountered disease entity which requires prompt surgical management as early as possible. The management of cholesteatoma is solely surgical.

Comparatively the pediatric population has higher rates of recurrent and residual disease, possibly due to anatomic and physiologic differences. Eustachian tube anatomy and dysfunction predisposes children to more frequent infections and retraction pockets. Thus posing a greater challenge than in adults in treating cholesteatom.

The goals of surgery are to eliminate epithelial and bone disease thoroughly and prevent the recurrence, produce a dry and safe ear and to restore serviceable hearing

Eligibility Criteria:
Inclusion Criteria:

- 1. Patient suffering from chronic suppurative otitis media, attico-antral (squamous) disease.

2. Age less than or equal to 18 years.

Exclusion Criteria:

- 1. Patient having an intracranial complication of chronic suppurative otitis media.

2. Bony erosion of sinus plate or dural plate or bone covering the Trautmann's triangle with granulations over the erosion in patients undergoing mastoid obliteration operation.
A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED)

This study will assess the bioequivalence of a Merck clinical trial formulation of ondansetron compared to a U.S. and non-U.S. marketed formulation of ondansetron.


Eligibility Criteria:
Inclusion Criteria:

* If female, subject is not pregnant or breast-feeding
* Subject is a nonsmoker
* Subject is in good general health

Exclusion Criteria:

* Subject has a history of high blood pressure, asthma, or cardiovascular, liver, neurologic, or kidney disease
* Subject is taking prescription or nonprescription drugs that can not be discontinued during the study
* Subject is a habitual and heavy consumer of caffeine
Programmed Intermittent Bolus Dosing Versus Continuous Epidural Infusion for Epidural Analgesia in Abdominal Surgery.

Epidurals are an effective means for providing neuraxial anesthesia and analgesia. Prior studies in labor epidurals have demonstrated that a programmed intermittent bolus application of local anesthesia can improve pain control by reducing the amount of local anesthetic required as well as improve patient satisfaction when compared to continuous epidural infusions. The effects of programmed intermittent bolus of epidural local anesthetics compared to continuous epidural infusions in a surgical setting have yet to be elucidated. Our goal is to evaluate the use of programmed intermittent bolus compared to continuous epidural infusion in a surgical patient population. We plan to enroll patients already undergoing abdominal surgeries including colorectal, gynecologic, surgical oncology, urological where epidural anesthesia can be employed. The primary endpoints of the study will be the total local anesthetic consumption and total opioid consumption as surrogate markers for the quality of epidural anesthesia. Secondary endpoints are pain scores and functional measurements, patient satisfaction, and incidence of hypotension.

See brief summary

Eligibility Criteria:
Inclusion Criteria:

* American Society of Anesthesia physical classification I - III, scheduled for surgery with anticipated an epidural anesthesia (including but not limited to colorectal, surgical oncology, urology, gynecology) as part of their perioperative treatment

Exclusion Criteria:

* Age younger than 18 years of age, non-English speaking, contraindication for neuraxial anesthesia (such as, but not limited to coagulopathy, infection at site, allergy to local anesthetic), preexisting neurologic deficits, inability to consent due to cognitive dysfunction, patients with pain numeric rating score \> 5 each day for greater than 3 months, daily opioid consumption \> 100 oral morphine equivalents for 14 consecutive days prior to surgery, patient refusal.
Observational Study of Norditropin NordiFlex® With NordiFlex PenMate™

This study is conducted in Europe. The aim of this study is to evaluate ease of injection of growth hormone in patients using Norditropin NordiFlex® with NordiFlex PenMate™. Convenience and tolerability of NordiFlex PenMate™ - an automatic injection and a needle hiding device - is also evaluated.


Eligibility Criteria:
Inclusion Criteria:

* After the physician decision has been made to use Norditropin Nordiflex® growth hormone therapy in accordance with the locally approved labelling, any subject is eligible for the study, including newly diagnosed subjects who have never received growth hormone therapy before and subjects who were treated with the other growth hormone products (with exclusion of patients who received previously Norditropin Nordiflex®) and need to be switched to a new product. The selection of the subjects will be at the discretion of the individual physician

Exclusion Criteria:

* Contraindications to Norditropin® growth hormone therapy
* Subjects who have received Norditropin NordiFlex® prior to this study
The Role of N-acetylcysteine as a Novel Adjuvant Treatment in Acute Organophosphorus Pesticide Poisoning

All patients admitted in the ICU of the PCC-ASUH due to acute poisoning by acute organophosphorus poisoning will be included in the study. The diagnosis of intoxication will be based on history of acute exposure , clinical examination and laboratory investigations. Patients will be randomly allocated into 2 equal groups.

Group 1 -. Patients who will receive (conventional treatment of acute organophosphorus poisoning plus NAC) and Group 2 - Patients who will receive conventional treatment only

40 patients with acute organophosphorus poisoning will be randomly assigned as control groups and study group in a 1:1 ratio ( 20 patients in each group). The diagnosis of acute organophosphorus intoxication will be based on history of acute exposure, clinical examination and laboratory investigations. Patients will be randomly allocated into 2 equal groups.

Group 1 - Patients who will receive (conventional treatment of acute organophosphorus poisoning plus NAC) Group 2 - Patients who will receive conventional treatment only

Eligibility Criteria:
Inclusion Criteria:

All patients (above 16 years) admitted to the ICU of the PCC-ASUH due to acute poisoning by acute organophosphorus poisoning will be included in the study. The diagnosis of intoxication will be based on history of acute exposure, clinical examination and laboratory investigations. -

Exclusion Criteria:

* Based on the possibility of alteration in measured parameters and/or biomarkers, patients below 16 years or above 60 years Patients with history of diabetes, cardiac disease, respiratory, renal disease and hepatic disease.
The Therapeutic Evaluation(Both Short-term and Long-term Outcome) of Minimal Invasive Radical Antegrade Modular Pancreatosplenectomy for Left-sided Pancreatic Cancer Patients

Pancreatic cancer is regarded as "the king of cancer". It is extremely malignant, with a low sensibility to chemotherapy and radiotherapy, and a poor prognosis. Surgical treatment is very important for pancreatic cancer. Radical antegrade modular pancreatosplenectomy (RAMPS) is a standard method for treating pancreatic cancer at the body and tail of pancreas. In the same surgical approach, the investigators are going to compare and discuss the advantages of laparoscopic and open RAMPS in the RCT study.

Open RAMPS is widely used now to treat pancreatic cancer at the body and tail of pancreas. Meanwhile, laparoscopic surgery is proved to have many advantages in other operations. According to primary retrospective study of open and laparoscopic RAMPS, there was no statistically significant difference in the long-term follow-up situations between these two groups, indicating the safety of both this two surgical approaches. The investigators would like to promote a prospective RCT study, to give more evidences of the superiority of laparoscopic RAMPS.

Eligibility Criteria:
Inclusion Criteria:

1. 18 years old and older;
2. Pathology diagnosed as pancreatic adenocarcinoma or suspect cancer mass at the pancreatic body or tail;
3. Patients who are eligible and planned to be performed RAMPS procedure;
4. Resectable or borderline resectable tumor by preoperative evaluation.

Exclusion Criteria:

1. Patients with evidence of distant metastasis or advanced arterial invasion so that are not able to continue radical surgery;
2. ASA≥4；
3. Patients who are not willing to be performed open and/or mi-RAMPS;
4. Not pancreatic adenocarcinoma by posteroperative pathology.
New Generation Rehabilitation Approach in Children With Dysfunctional Voiding

The investigators hypothesize that Dynamic Neuromuscular Stabilization training, a next-generation exercise approach, and transabdominal ultrasound-guided pelvic floor muscle training (PFMT) will be more effective than PFMT guided solely by transabdominal ultrasound in reducing post-void residual volume, improving voiding disorder symptoms, and enhancing pelvic floor muscle relaxation in children with dysfunctional voiding.


Eligibility Criteria:
Inclusion Criteria:

* Children aged 6-14 years,
* Diagnosed with dysfunctional urination according to uroflowmetry measurement results and clinical examination findings,
* Children who consent to participate in the study with the consent of their mother, father or legal guardian (legal representative) will be included in the study.

Exclusion criteria:

* Children under 6 years of age,
* Those with anatomical changes in the urinary system,
* Those with spina bifida,
* Those with a history of active urinary tract infection,
* Those with a neurological disease,
* Those with accompanying respiratory system disease,
* Those with cognitive impairment,
* Those with mental retardation,
* Children whose bladder image is unclear in the pelvic floor evaluation with US,
* Children who have previously undergone orthopedic surgery will not be included in the study.

PS:

* Children who cannot comply with the application of pelvic floor muscle training,
* Children who have missed 2 or more sessions of the treatment program will be excluded from the study.